Orforglipron
An investigational, once-daily oral non-peptide GLP-1 receptor agonist being developed for weight management and type 2 diabetes.
Unlike semaglutide (which is an injected peptide) or Rybelsus (which is a peptide requiring strict fasting protocols to be absorbed orally), orforglipron is a small molecule drug. This allows it to be absorbed easily in pill form without strict dietary restrictions.
Early clinical trials show that orforglipron produces weight loss comparable to injectable GLP-1 therapies, making it a highly anticipated alternative for patients who have needle phobia or want a more convenient administration method.